NCT00219752View on ClinicalTrials.gov

Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2002

Study Completion Date

May 31, 2007

Conditions
Chronic Myeloid Leukemia
Interventions
DRUG

Imatinib mesylate 400 mg

Trial Locations (1)

86021

University Hospital, Poitiers

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Poitiers University Hospital

OTHER